Bailard’s BioMarin Pharmaceuticals BMRN Stock Holding History

Bailard’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,929	Closed	-$226K	–	696
2022 Q1	$226K	Sell	2,929 -586	-17%	-$49K	0.01%	632
2021 Q4	$311K	Buy	+3,515	New	+$290K	0.01%	522
2021 Q3	–	Sell	-4,000	Closed	-$334K	–	711
2021 Q2	$334K	Hold	4,000	–	–	0.01%	490
2021 Q1	$302K	Hold	4,000	–	–	0.01%	516
2020 Q4	$351K	Hold	4,000	–	–	0.02%	405
2020 Q3	$304K	Hold	4,000	–	–	0.02%	387
2020 Q2	$493K	Hold	4,000	–	–	0.03%	271
2020 Q1	$338K	Hold	4,000	–	–	0.02%	287
2019 Q4	$338K	Hold	4,000	–	–	0.02%	382
2019 Q3	$270K	Hold	4,000	–	–	0.02%	422
2019 Q2	$343K	Hold	4,000	–	–	0.02%	381
2019 Q1	$355K	Sell	4,000 -1,000	-20%	-$92.7K	0.02%	378
2018 Q4	$426K	Hold	5,000	–	–	0.03%	334
2018 Q3	$485K	Hold	5,000	–	–	0.03%	383
2018 Q2	$471K	Buy	5,000 +1,000	+25%	+$87.6K	0.03%	379
2018 Q1	$324K	Sell	4,000 -100	-2%	-$8.58K	0.02%	401
2017 Q4	$366K	Buy	+4,100	New	+$357K	0.02%	350
2016 Q1	–	Sell	-2,000	Closed	-$210K	–	264
2015 Q4	$210K	Buy	+2,000	New	+$209K	0.09%	188

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Bailard's BMRN Position: Q2 2022 in Review

Bailard sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 2,929 shares — an estimated $226K sold.

Bailard first reported a position in BMRN in Q4 2015 and held it in 18 quarters. The position peaked at $493K in Q2 2020. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Bailard reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Bailard sold 2,929 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $226K.
Bailard first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 18 quarters.
Bailard's BioMarin Pharmaceuticals position peaked at $493K in Q2 2020.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Bailard's 13F filing for Q2 2022, filed 27 Jul 2022.